How Visceral Fat Causes Inflammation and Disease

Not all body fat behaves the same way. The fat packed deep around your abdominal organs is the kind most tied to type 2 diabetes, heart disease and liver trouble. This fat does more than store energy: it sends out chemical signals and fatty fuel that keep the body in a quiet, constant state of inflammation.¹ The harm works through other organs, which is why two people of the same weight can face very different health risks.² The process can also be turned back, because shrinking this fat tends to calm the inflammation it causes.³

Why Fat Around Your Organs Is Different

Visceral fat lies inside the abdomen, wrapped around the intestines in sheets of tissue. Subcutaneous fat is the soft layer you can pinch under the skin.⁴ Blood leaving visceral fat travels through the portal vein straight to the liver before it reaches anywhere else.⁵ Fat on the hips or thighs drains into general circulation and is diluted before it gets to the liver, so a modest amount of deep belly fat can matter more than a larger amount stored elsewhere.

Pinchable fat on your hips, thighs and the surface of your belly is mostly subcutaneous. A firm, round belly that pushes outward often reflects fat behind the abdominal wall. Slim-looking people can still carry hidden visceral fat, and men, along with women after menopause, tend to store more of their fat deep in the belly.

The cells themselves behave differently too. Visceral fat cells break down their stored fat faster and respond less to insulin, the hormone that normally tells them to hold on to it.⁶ They release more free fatty acids, the loose fat molecules cells burn or store, into the blood.⁷ This tissue also holds more blood vessels, nerves and immune cells than fat under the skin. Fat under the skin, meanwhile, is better at soaking up fat circulating in the blood, acting more like a safe storage tank.⁸

The chemical signals differ as well. Fat under the skin makes more of the hormones leptin and adiponectin, while visceral fat makes more inflammatory signals.⁹ So the same amount of fat can do more harm when it sits deep in the belly.

How Visceral Fat Becomes Inflamed

As people gain weight, fat cells swell, but new blood vessels don’t keep pace.¹⁰ Parts of the tissue become short of oxygen.¹¹ Oxygen-starved fat cells then switch on genes that lay down stiff, scar-like tissue.¹² Enlarged fat cells also lose their ability to store more fat, so the extra spills into the blood and other organs.¹³

When a fat cell is stretched to its limit or starved of oxygen, it can die and spill its fatty contents into the surrounding tissue. The immune system treats that spilled material as debris and damage, and sends cells to clear it away. New fat cells keep reaching the same limit while the weight is carried, so the cleanup never ends and the immune cells stay.

In obese animals, the immune cells in visceral fat shift from a calming type to an aggressive, inflammation-driving type.¹⁴ They gather in rings around dying fat cells.¹⁵ In obese mice, these immune cells account for about 80% of the inflammation-sustaining alarm activity in the fat.¹⁶

Inflamed visceral fat releases large amounts of inflammatory signals and fatty acids into the blood.¹⁷ One of the main signals is IL-6, an inflammatory messenger that tells other tissues to stay on alert.¹⁸ Overweight men with the same BMI but more visceral fat had blood IL-6 levels about 65% higher.¹⁹ Fat cells react to these signals by becoming more inflamed themselves, which feeds a loop.²⁰

This is called low-grade inflammation because it looks nothing like the redness and swelling of an infected cut. You usually can’t feel it at all. It simmers for years rather than days and shows up mainly as subtle shifts in blood markers.

How It Leads to Diabetes and Fatty Liver

Because visceral fat drains into the liver, the liver gets a heavy, direct dose of fatty acids and inflammatory signals.²¹ It starts storing fat and stops responding properly to insulin.²² The result is that it keeps making sugar even when blood sugar is already high.²³

Insulin normally works after a meal: it tells muscle, liver and fat cells to take sugar out of the blood. Insulin resistance means cells ignore that message, so sugar stays in the blood instead of moving into muscle and liver. Inflammatory signals cause this by switching on stress pathways inside cells that directly jam insulin’s message.²⁴

When cells respond poorly, the pancreas first makes more insulin to push the same amount of sugar in. For years this extra effort keeps blood sugar normal, so insulin resistance can be present long before any sugar test is abnormal.

Years of high blood fatty acids also impair the pancreas’s ability to release insulin in people genetically prone to diabetes.²⁵ When the pancreas can no longer make up for the resistance, blood sugar rises into the type 2 diabetes range. Routine blood tests may hint at the trouble well before then: fasting glucose creeping into the prediabetes range of 100 to 125 mg/dL, raised triglycerides, and liver enzymes slightly above normal.

The liver is affected too. In people with severe obesity, more inflammatory signals in their fat went with more serious, inflamed fatty liver.²⁶ Fatty liver usually causes no symptoms and is often found by chance on an ultrasound. If visceral fat stays high, it can progress to inflammation and scarring.

Effects on the Heart, Blood Vessels and Cancer Risk

Visceral fat is highly inflamed in people with metabolic syndrome or coronary artery disease, and it appears to be directly involved in the build-up of artery plaque.²⁷ Fat wrapped around blood vessels sends signals straight into the vessel wall.²⁸ In obesity this fat becomes inflamed and leaves vessels stiffer and less able to relax.²⁹ Blood pressure and the risk of heart attack and stroke climb as a result.

Inflammatory signals make the lining of the artery more likely to catch fats and immune cells from the blood. Immune cells that enter the wall take up fat and become foamy cells, which form the core of a plaque. A plaque can narrow the artery or crack open, and a clot forming on a cracked plaque is what usually triggers a heart attack or stroke.

Metabolic syndrome is the name for a cluster of problems: a large waist, high blood pressure, high blood sugar, high triglycerides and low HDL cholesterol. Visceral fat links them through shared inflammation. Having three or more of these factors usually counts as the syndrome, and each one adds to heart risk.

Cancer risk is touched as well. Excess fat converts other hormones into estrogen, and higher estrogen can drive cell growth in the lining of the womb, raising endometrial cancer risk.³⁰ IL-6 helps breast cancer cells move and increases estrogen production, and is linked to worse outlook.³¹

How to Tell If You Carry Too Much Visceral Fat

A waist over 40 inches (102 cm) in men or 35 inches (88 cm) in women signals high risk. Some guidelines use lower cutoffs for people of Asian descent, about 35 inches for men and 31 inches for women.

To measure well, stand relaxed and breathe out normally. Place the tape just above the hip bones, level all the way round, without pulling it tight or sucking in. Measure at the same time of day if you want to track change.

A waist measurement estimates the total fat in the belly and can’t separate visceral fat from fat under the skin. It is still useful, because a larger waist goes with more visceral fat on average and with higher risk of diabetes and heart disease. A waist below the cutoff doesn’t guarantee low visceral fat, and one above it is a reason to look at other risk markers, not a diagnosis.

Scans measure it more directly. DXA body scans, the same low-dose X-ray used for bone density, can estimate visceral fat. Their estimates track insulin levels about as well as CT scans do, without CT’s higher radiation.³² Once overall weight is taken into account, though, scan-measured visceral fat says little about blood inflammation markers.³³

A CRP blood test measures inflammation; your doctor may order it as a high-sensitivity (hs-CRP) test. It rises with any inflammation, including colds, so it doesn’t pinpoint visceral fat as the cause.

Reducing Visceral Fat Calms the Inflammation

In one trial, exercise alone cut abdominal fat by about 2.6 percentage points and liraglutide alone by about 2.8.³⁴ Combining the two cut it by about 6.1 points and was the only approach that lowered CRP, by 43%.³⁵ A fall in CRP suggests the body’s low-level inflammation is easing. These are averages in one group of people, so an individual’s results can differ.

Liraglutide belongs to the GLP-1 drugs, a class that includes semaglutide. Across many studies, GLP-1 drugs reduced visceral fat and liver fat, in people with or without diabetes.³⁶ In obese mice, semaglutide shrank fat cells and cut inflammatory signals in visceral fat by roughly half or more.³⁷

If you’re considering GLP-1 drugs such as semaglutide or liraglutide, it helps to ask your doctor whether your blood sugar, liver tests or heart risk make you eligible. Ask about common side effects such as nausea. Weight tends to return if the drug stops, and these medicines work best alongside exercise.

Visceral fat tends to shrink faster than fat under the skin once you lose weight. Even modest weight loss of 5 to 10% can improve blood sugar and liver fat. Regular aerobic exercise, like brisk walking for 150 minutes a week, is a strong first step.

Sit-ups and similar moves won’t target belly fat, because you can’t burn fat from one chosen spot. Overall calorie balance and whole-body activity matter most. Strength training still helps by building muscle that uses sugar.

Sleep, Body Clock, Diet and Other Influences

Night owls had more inflammatory signals in their visceral fat than early risers, even at similar body size.³⁸ In mice, a constantly shifted schedule erased the normal daily rhythm of fat inflammation and kept it high.³⁹ Regular sleep and meal times may help keep fat inflammation in check.

The finding in night owls shows a link, not proof that a late schedule causes the inflammation. For shift workers, it makes sense to keep meal times as regular as possible, avoid large meals in the middle of the night, and protect daytime sleep with darkness and quiet.

Diet matters through the gut. Very high-fat diets reduce some helpful gut bacteria.⁴⁰ The gut lining becomes leakier and bacterial toxins enter the blood, adding to inflammation.⁴¹ Boosting those bacteria with fiber lowered the toxins.⁴²

In practice, that means adding fiber from beans, oats, onions and vegetables, and cutting back on fried and highly processed fatty foods. Limit sugary drinks, which add belly fat, and swap some saturated fat for olive oil or nuts.

Age and environment play a part too. Worn-out, aged cells pile up in fat with age and release inflammatory signals.⁴³ Some chemicals in plastics and some flame retardants may increase visceral fat.⁴⁴ Estrogen helps protect fat from inflammation, which may explain why risk rises after menopause.⁴⁵

1
PubMed. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis ↩︎
2
PubMed. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men ↩︎
3
PubMed Central. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial ↩︎
4
PubMed. Subcutaneous and visceral adipose tissue: structural and functional differences ↩︎
5
PubMed. Subcutaneous and visceral adipose tissue: structural and functional differences ↩︎
6
PubMed Central. Metabolic alterations following visceral fat removal and expansion ↩︎
7
PubMed. Subcutaneous and visceral adipose tissue: structural and functional differences ↩︎
8
PubMed. Subcutaneous and visceral adipose tissue: structural and functional differences ↩︎
9
PubMed Central. Metabolic alterations following visceral fat removal and expansion ↩︎
10
PubMed Central. Hypoxia induces stress fiber formation in adipocytes in the early stage of obesity ↩︎
11
PubMed Central. Hypoxia induces stress fiber formation in adipocytes in the early stage of obesity ↩︎
12
PubMed Central. Hypoxia induces stress fiber formation in adipocytes in the early stage of obesity ↩︎
13
PubMed. Dysfunctional fat cells, lipotoxicity and type 2 diabetes ↩︎
14
PubMed Central. Adipose-Tissue and Intestinal Inflammation – Visceral Obesity and Creeping Fat ↩︎
15
PubMed Central. Adipose-Tissue and Intestinal Inflammation – Visceral Obesity and Creeping Fat ↩︎
16
PubMed Central. Externalized Inflammasomes in Visceral Fat Sustain Obesity-Related Inflammation ↩︎
17
PubMed. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis ↩︎
18
PubMed. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men ↩︎
19
PubMed. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men ↩︎
20
PubMed Central. IL-6 and TNF-α Induced Obesity-Related Inflammatory Response Through Transcriptional Regulation of miR-146b ↩︎
21
PubMed. Visceral fat and metabolic inflammation: the portal theory revisited ↩︎
22
PubMed. Visceral fat and metabolic inflammation: the portal theory revisited ↩︎
23
PubMed. Dysfunctional fat cells, lipotoxicity and type 2 diabetes ↩︎
24
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.. Visceral fat and insulin resistance – what we know? ↩︎
25
PubMed. Dysfunctional fat cells, lipotoxicity and type 2 diabetes ↩︎
26
PubMed. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity ↩︎
27
PubMed. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis ↩︎
28
PubMed Central. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease ↩︎
29
PubMed Central. Obesity, Adipose Tissue and Vascular Dysfunction ↩︎
30
PubMed Central. Visceral adiposity, insulin resistance and cancer risk ↩︎
31
PubMed Central. Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis ↩︎
32
PubMed Central. Comparison of Associations of DXA and CT Visceral Adipose Tissue Measures with Insulin Resistance, Lipid Levels, and Inflammatory Markers ↩︎
33
PubMed Central. Comparison of Associations of DXA and CT Visceral Adipose Tissue Measures with Insulin Resistance, Lipid Levels, and Inflammatory Markers ↩︎
34
PubMed Central. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial ↩︎
35
PubMed Central. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial ↩︎
36
PubMed Central. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis ↩︎
37
PubMed. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice ↩︎
38
PubMed Central. Chronodisruption enhances inflammatory cytokine release from visceral adipose tissue in obesity ↩︎
39
PubMed Central. Chronic circadian shift leads to adipose tissue inflammation and fibrosis ↩︎
40
British Journal of Nutrition. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia ↩︎
41
British Journal of Nutrition. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia ↩︎
42
British Journal of Nutrition. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia ↩︎
43
PubMed Central. Adipose tissue aging: mechanisms and therapeutic implications ↩︎
44
PubMed Central. Endocrine Disruptors Leading to Obesity and Related Diseases ↩︎
45
PubMed Central. The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis ↩︎